Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery - PubMed (original) (raw)

doi: 10.1038/nm739. Epub 2002 Jul 22.

Yasuhiro Ikeda, Yoshitaka Iwanaga, Susumu Minamisawa, Moto-o Date, Yusu Gu, Mitsuo Iwatate, Manxiang Li, Lili Wang, James M Wilson, Yibin Wang, John Ross Jr, Kenneth R Chien

Affiliations

• PMID: 12134142
• DOI: 10.1038/nm739

Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery

Masahiko Hoshijima et al. Nat Med. 2002 Aug.

Abstract

The feasibility of gene therapy for cardiomyopathy, heart failure and other chronic cardiac muscle diseases is so far unproven. Here, we developed an in vivo recombinant adeno-associated virus (rAAV) transcoronary delivery system that allows stable, high efficiency and relatively cardiac-selective gene expression. We used rAAV to express a pseudophosphorylated mutant of human phospholamban (PLN), a key regulator of cardiac sarcoplasmic reticulum (SR) Ca(2+) cycling in BIO14.6 cardiomyopathic hamsters. The rAAV/S16EPLN treatment enhanced myocardial SR Ca(2+) uptake and suppressed progressive impairment of left ventricular (LV) systolic function and contractility for 28-30 weeks, thereby protecting cardiac myocytes from cytopathic plasma-membrane disruption. Low LV systolic pressure and deterioration in LV relaxation were also largely prevented by rAAV/S16EPLN treatment. Thus, transcoronary gene transfer of S16EPLN via rAAV vector is a potential therapy for progressive dilated cardiomyopathy and associated heart failure.

PubMed Disclaimer

Similar articles

• Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats.
  Iwanaga Y, Hoshijima M, Gu Y, Iwatate M, Dieterle T, Ikeda Y, Date MO, Chrast J, Matsuzaki M, Peterson KL, Chien KR, Ross J Jr. Iwanaga Y, et al. J Clin Invest. 2004 Mar;113(5):727-36. doi: 10.1172/JCI18716. J Clin Invest. 2004. PMID: 14991071 Free PMC article.
• Heart failure-inducible gene therapy targeting protein phosphatase 1 prevents progressive left ventricular remodeling.
  Miyazaki Y, Ikeda Y, Shiraishi K, Fujimoto SN, Aoyama H, Yoshimura K, Inui M, Hoshijima M, Kasahara H, Aoki H, Matsuzaki M. Miyazaki Y, et al. PLoS One. 2012;7(4):e35875. doi: 10.1371/journal.pone.0035875. Epub 2012 Apr 27. PLoS One. 2012. PMID: 22558250 Free PMC article.
• Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy.
  Minamisawa S, Hoshijima M, Chu G, Ward CA, Frank K, Gu Y, Martone ME, Wang Y, Ross J Jr, Kranias EG, Giles WR, Chien KR. Minamisawa S, et al. Cell. 1999 Oct 29;99(3):313-22. doi: 10.1016/s0092-8674(00)81662-1. Cell. 1999. PMID: 10555147
• Calcium regulatory proteins and their alteration by transgenic approaches.
  Dillmann WH. Dillmann WH. Am J Cardiol. 1999 Jun 17;83(12A):89H-91H. doi: 10.1016/s0002-9149(99)00268-4. Am J Cardiol. 1999. PMID: 10750595 Review.
• Sarcoplasmic reticulum Ca-ATPase-phospholamban interactions and dilated cardiomyopathy.
  Haghighi K, Gregory KN, Kranias EG. Haghighi K, et al. Biochem Biophys Res Commun. 2004 Oct 1;322(4):1214-22. doi: 10.1016/j.bbrc.2004.07.164. Biochem Biophys Res Commun. 2004. PMID: 15336969 Review.

Cited by

• Amelioration of laminin-alpha2-deficient congenital muscular dystrophy by somatic gene transfer of miniagrin.
  Qiao C, Li J, Zhu T, Draviam R, Watkins S, Ye X, Chen C, Li J, Xiao X. Qiao C, et al. Proc Natl Acad Sci U S A. 2005 Aug 23;102(34):11999-2004. doi: 10.1073/pnas.0502137102. Epub 2005 Aug 15. Proc Natl Acad Sci U S A. 2005. PMID: 16103356 Free PMC article.
• Exacerbation of dystrophic cardiomyopathy by phospholamban deficiency mediated chronically increased cardiac Ca2+ cycling in vivo.
  Law ML, Prins KW, Olander ME, Metzger JM. Law ML, et al. Am J Physiol Heart Circ Physiol. 2018 Dec 1;315(6):H1544-H1552. doi: 10.1152/ajpheart.00341.2018. Epub 2018 Aug 17. Am J Physiol Heart Circ Physiol. 2018. PMID: 30118340 Free PMC article.
• An emerging adeno-associated viral vector pipeline for cardiac gene therapy.
  Asokan A, Samulski RJ. Asokan A, et al. Hum Gene Ther. 2013 Nov;24(11):906-13. doi: 10.1089/hum.2013.2515. Hum Gene Ther. 2013. PMID: 24164238 Free PMC article. Review.
• Decreasing tropomyosin phosphorylation rescues tropomyosin-induced familial hypertrophic cardiomyopathy.
  Schulz EM, Wilder T, Chowdhury SA, Sheikh HN, Wolska BM, Solaro RJ, Wieczorek DF. Schulz EM, et al. J Biol Chem. 2013 Oct 4;288(40):28925-35. doi: 10.1074/jbc.M113.466466. Epub 2013 Aug 19. J Biol Chem. 2013. PMID: 23960072 Free PMC article.
• Time-resolved FRET reveals the structural mechanism of SERCA-PLB regulation.
  Dong X, Thomas DD. Dong X, et al. Biochem Biophys Res Commun. 2014 Jun 27;449(2):196-201. doi: 10.1016/j.bbrc.2014.04.166. Epub 2014 May 9. Biochem Biophys Res Commun. 2014. PMID: 24813991 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal